Nelzarabine CAS NO.121032-29-9

Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.

Nelarabine Basic information

Physical properties Developed by GlaxoSmithKline Pharmacology and pharmacokinetics Clinical trials Usage and dosage Note

Product Name:	Nelarabine
Synonyms:	NELARABINE;Nelzarabine [USAN];Nelzarabine;9beta-D-Arabinofuranosyl-6-methoxy-9H-purin-2-amine;(2R,3R,4S,5R)-2-(2-aMino-6-Methoxy-9H-purin-9-yl)-5-(hydroxyMethyl)-tetrahydrofuran-3,4-diol;Nelarabine (Arranon);506u;9-β-D-Arabinofuranosyl-6-Methoxy-9H-purin-2-aMine
CAS:	121032-29-9
MF:	C11H15N5O5
MW:	297.27
EINECS:
Product Categories:	Bases & Related Reagents;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;5g,10g,25g,100g;ARRANON;Anti-cancer&immunity;API;Inhibitors
Mol File:	121032-29-9.mol

Nelarabine is mainly used for patients who have received at least two chemotherapy regimens but still have no response, or have occurred recurrent acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
Adult patients received nelarabine i.v. over 2 hours on days 1, 3 and 5 in every 21 days with the recommendation dose of 1500mg/m2 in every 21 days and without dilution; pediatric patients received this regimen over 1 hour for 5 consecutive days with the recommendation dose of 650mg/m2 in every 21 days, without dilution.  The recommended treatment period for adults and children is unspecified. In clinical trials, unless the patient get worse and cannot tolerate toxicity. They should treated with bone marrow transplant immediately or no longer be treated.